Aspire Biopharma Holdings, Inc. (ASBP)
| Market Cap | 3.63M -95.9% |
| Revenue (ttm) | 1,941 |
| Net Income | -20.54M |
| EPS | -16.59 |
| Shares Out | 2.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,744,057 |
| Open | 1.290 |
| Previous Close | 1.410 |
| Day's Range | 1.210 - 1.390 |
| 52-Week Range | 1.210 - 632.000 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 24, 2026 |
About ASBP
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it i... [Read more]
Financial Performance
Financial StatementsNews
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements
ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending d...
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (N...
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit
ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a propri...
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution
ESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a stra...
Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin
Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing. ESTE...
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks
New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel. Clopidogrel, currently sold under the brand name Plavix®, w...
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology ESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdin...
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign
New streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand through educational and lifestyle content...
Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and generalized anxiety disorders Alprazolam, sold under the brand name Xanax® among others, ...
Aspire Biopharma Announces Reverse Stock Split
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug de...
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma Hol...
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine
A highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support BUZZ BOMB™ will power Ashley's elite training, recovery, and lifes...
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, re...
Aspire Biopharma Provides Q3 2025 Business Update
ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, tod...
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology...
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, ha...
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today...
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform
ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, t...
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025
Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabet...
Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization Future Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / O...
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product
BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_s...
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement
Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ ...
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin's effect on platelet aggreg...
Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)
According to the NIH , Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths Trial demonstrates dramaticall...